Halberd Partnership Secures Contract from Defense Atomics Corporation for Treatment of Brain Injury and PTSD Page 1

Contributing funding and an important additional tool to combat PTSD and TBI

JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) — Halberd Corporation (OTC PINK: HALB), in collaboration with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award. Defense Atomics Corporation has agreed to collaborate with the Halberd/Athena teams and to fund important advanced research, including the ongoing FDA IND study utilizing Halberd’s LDX technology and Athena Corporation’s WatchDawg monitoring technology.

Defense Atomics Corporation has agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics’ success with the CRISPR methodology in patients overseas, this study is designed to substantiate the benefits of this technology when combined with Halberd/Athena’s LDX PTSD and TBI/Brain Injury protocol.